[go: up one dir, main page]

MX2014003883A - Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados. - Google Patents

Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.

Info

Publication number
MX2014003883A
MX2014003883A MX2014003883A MX2014003883A MX2014003883A MX 2014003883 A MX2014003883 A MX 2014003883A MX 2014003883 A MX2014003883 A MX 2014003883A MX 2014003883 A MX2014003883 A MX 2014003883A MX 2014003883 A MX2014003883 A MX 2014003883A
Authority
MX
Mexico
Prior art keywords
metabolic diseases
treatment
related disorders
lipase inhibitors
monoacylglycerol lipase
Prior art date
Application number
MX2014003883A
Other languages
English (en)
Inventor
Christopher M Flores
Mark J Macielag
Margery Connelly
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2014003883A publication Critical patent/MX2014003883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos, composiciones y métodos para tratar enfermedades metabólicas que incluyen obesidad y diabetes; tales compuestos están representados por la fórmula (I) como sigue: En donde Y y Z se definen en la presente descripción.
MX2014003883A 2011-09-30 2012-09-27 Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados. MX2014003883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541403P 2011-09-30 2011-09-30
PCT/US2012/057470 WO2013049293A1 (en) 2011-09-30 2012-09-27 Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders

Publications (1)

Publication Number Publication Date
MX2014003883A true MX2014003883A (es) 2014-08-27

Family

ID=47116336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003883A MX2014003883A (es) 2011-09-30 2012-09-27 Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.

Country Status (10)

Country Link
US (1) US9375430B2 (es)
EP (1) EP2760451A1 (es)
JP (1) JP2014528429A (es)
KR (1) KR20140068241A (es)
CN (1) CN103841973A (es)
AR (1) AR088087A1 (es)
CA (1) CA2850100A1 (es)
MX (1) MX2014003883A (es)
TW (1) TW201328695A (es)
WO (1) WO2013049293A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015099196A1 (en) 2013-12-26 2015-07-02 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
WO2016158956A1 (ja) 2015-03-30 2016-10-06 武田薬品工業株式会社 複素環化合物
EP3438109B1 (en) 2016-03-31 2021-08-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
EP3689879B1 (en) 2017-09-29 2025-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
EP2049520A4 (en) * 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc indole compounds
FR2915199B1 (fr) * 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915198B1 (fr) * 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
WO2009117444A1 (en) 2008-03-17 2009-09-24 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
JP5649644B2 (ja) * 2009-04-22 2015-01-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド

Also Published As

Publication number Publication date
US20130085130A1 (en) 2013-04-04
AR088087A1 (es) 2014-05-07
JP2014528429A (ja) 2014-10-27
CA2850100A1 (en) 2013-04-04
EP2760451A1 (en) 2014-08-06
TW201328695A (zh) 2013-07-16
US9375430B2 (en) 2016-06-28
WO2013049293A1 (en) 2013-04-04
KR20140068241A (ko) 2014-06-05
CN103841973A (zh) 2014-06-04

Similar Documents

Publication Publication Date Title
PH12012502128B1 (en) Chemical compounds
IN2014CN04907A (es)
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MY164354A (en) Asymmetric ureas and medical uses thereof
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX2011009493A (es) Compuestos para el tratamiento de trastornos metabolicos.
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
MX348311B (es) Inhibidores nampt.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
IN2012DN03846A (es)
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
GB201116017D0 (en) Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
GB201114389D0 (en) Novel compounds
MX353062B (es) Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas.
MX339513B (es) Derivados de sec-hidroxiciclohexilo como inhibidores de lipasa sensible a hormonas (hsl) para el tratamiento de diabetes.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
PH12013501665A1 (en) Cathepsin c inhibitors
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
MX2014002343A (es) Inhibidores de parp.